SLC5A2 and diabetic kidney disease: To do this, we measured urinary TNFR1 and CCL2 post hoc in the IMPROVE clinical crossover study of the sodium-glucose cotransporter 2 inhibitor dapagliflozin in DKD (n = 33).56